Apr. 13 at 7:40 PM
$HYDTF $VSQTF Looks like they sell more the semaglutide as seen below but according to the webinar it doesn't matter anyways and looks like our projections haven't changed. I know there's semaglutide sodium and other ways of working around it. In the webinar, they said q1 that passed was similar to the projection of 25 M in rev, thats 100 M in annualized revenue already.